A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril
in patients with left ventricular dysfunction after myocaxdial infarction: Trandolapril
Cardiac Evaluation (TRACE) Study Group.
reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.
5 mg QD Trandolapril
Mavik 1 mg QD (2 mg QD in African- American patients) Classification/Drug Usual Dosage Range Benazepril 20-40 mg QD Captopril (*) 25-150 mg BID-TID Enalapril 10-40 mg QD or in divided doses Fosinopril 20-40 mg QD Lisinopril 20-40 mg QD Moexipril 7.
The PEACE trial is a randomized, multi-center study of trandolapril
vs placebo in 8,290 patients with stable coronary artery disease (CAD).
Oysa sol ventrikul disfonksiyonu olan miyokard infarktusu hastalarinda (50), trandolapril
yeni AF riskini %5.
Reddy's Receives FDA Approval for Trandolapril
The angiotensin converting enzyme inhibitor trandolapril
has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function.
The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) trial, which was designed to confirm the advantage of an RAS blocker, found no difference in the rate of cardiovascular end points with trandolapril
, compared with placebo.
8, 1996--TARKA(R), a combination of the ACE inhibitor trandolapril
and the calcium channel blocker verapamil HCl ER, has received U.
PEACE involved the double-blind randomization of patients with stable coronary artery disease (CAD) and normal left ventricular systolic function to the ACE inhibitor trandolapril
or placebo on top of modern conventional therapy with other drugs of proven effectiveness.
In the International Verapamil-SR Trandolapril
Study (INVEST), a [beta]-blocker (atenolol) based strategy was associated with a 17% risk of new onset diabetes compared to a verapamil strategy (17).
The Bergamo Nephrologic Diabetes Complication Trial (BENEDICT) aimed to evaluate the impact of the ACE inhibitor trandolapril
and the calcium channel blocker verapamil during the onset of microalbuminuria.
8 years after 8,290 PEACE participants at 187 sites were randomized in double-blind fashion to a target dose of 4 mg/day trandolapril
or placebo, the incidence of the primary end point--a composite of cardiovascular death, acute MI, or coronary revascularization--was virtually identical in the two groups: 21.
Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Trandolapril
Tablets, 1 mg, 2 mg and 4 mg.
no generic available 1-4 mg/day Available in trade [Mavik] [$0.